Karuna Therapeutics
Pushing the boundaries of neuroscience to transform the treatment of mental illness
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- karunatx.com
- Total Funding
- $12.0M
- Last Round
- $12.0M Extension RoundApr 2019
- Rounds
- 1
About
Karuna Therapeutics was a clinical-stage biopharmaceutical company developing novel muscarinic receptor modulators for the treatment of schizophrenia, Alzheimer's disease psychosis, and other psychiatric conditions. Its lead candidate, KarXT (xanomeline-trospium), received FDA approval as Cobenfy — the first new schizophrenia mechanism in decades. Karuna was founded in 2018 as a PureTech Health company and was acquired by Bristol Myers Squibb in March 2024 for $14 billion, representing one of the largest neuroscience acquisitions in pharmaceutical history.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Apr 2019
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
BridgeBio makes targeted treatments for genetic diseases.